Mary Kay Fenton - 18 Feb 2026 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Reporting relationship: Chief Financial Officer
Issuer ticker: CGEM
Reported as of: 18 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2026, 17:00:05 UTC
Prior SEC filing: 05 Jan 2026
Next SEC filing: 23 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Jacquelyn Sumer, Attorney-in-Fact

Filing notes and source

Key filing fact

Mary Kay Fenton filed Form 4 for Cullinan Therapeutics, Inc. (CGEM) on 19 Feb 2026.

Key facts

This page summarizes Mary Kay Fenton's Form 4 filing for Cullinan Therapeutics, Inc. (CGEM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2026, 17:00.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001378589 Primary reporting owner

Fenton Mary Kay

Relationship: Chief Financial Officer
Address: C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE
Signature: /s/ Jacquelyn Sumer, Attorney-in-Fact
Signature date: 19 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CGEM transaction

Common Stock

Award

Transaction value: $0
Shares: +68,750
Change %: +111%
Price: $0.000000
Shares after: 130,778
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CGEM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +137,500
Change %
Price: $0.000000
Shares after: 137,500
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 137,500
Exercise price: $12.44
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares underlying the restricted stock unit vest on an annual basis over four years.

Footnote F2

The shares underlying the option vest over four years, with one forty-eighth (1/48th) of the shares vesting in equal monthly installments until the fourth anniversary of the grant date.